News headlines about Alkermes (NASDAQ:ALKS) have trended somewhat positive on Friday, according to Accern Sentiment Analysis. The research firm ranks the sentiment of media coverage by monitoring more than 20 million news and blog sources. Accern ranks coverage of publicly-traded companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Alkermes earned a media sentiment score of 0.12 on Accern’s scale. Accern also assigned news coverage about the company an impact score of 45.5725444871458 out of 100, indicating that recent media coverage is somewhat unlikely to have an impact on the stock’s share price in the near term.

These are some of the news articles that may have effected Accern’s scoring:

Shares of Alkermes (NASDAQ:ALKS) traded down $0.40 during mid-day trading on Friday, hitting $54.14. The company had a trading volume of 483,100 shares, compared to its average volume of 713,675. The company has a current ratio of 3.05, a quick ratio of 2.72 and a debt-to-equity ratio of 0.23. Alkermes has a twelve month low of $46.42 and a twelve month high of $63.40. The company has a market cap of $8,330.00, a P/E ratio of -48.77 and a beta of 2.13.

Alkermes (NASDAQ:ALKS) last announced its quarterly earnings data on Thursday, October 26th. The company reported $0.03 earnings per share for the quarter, topping the consensus estimate of ($0.01) by $0.04. Alkermes had a negative return on equity of 7.27% and a negative net margin of 20.12%. The business had revenue of $217.40 million during the quarter, compared to the consensus estimate of $231.29 million. During the same period in the prior year, the company earned ($0.09) EPS. Alkermes’s revenue for the quarter was up 20.6% on a year-over-year basis. analysts anticipate that Alkermes will post -0.59 EPS for the current year.

A number of analysts have recently weighed in on the company. Credit Suisse Group set a $66.00 target price on Alkermes and gave the company a “buy” rating in a research report on Tuesday, November 28th. Barclays downgraded Alkermes from an “overweight” rating to an “equal weight” rating and dropped their price objective for the stock from $66.00 to $50.00 in a research report on Monday, October 16th. JPMorgan Chase & Co. set a $78.00 price objective on Alkermes and gave the stock a “buy” rating in a research report on Friday, October 27th. UBS Group set a $54.00 price objective on Alkermes and gave the stock a “hold” rating in a research report on Friday, October 27th. Finally, Mizuho set a $81.00 price objective on Alkermes and gave the stock a “buy” rating in a research report on Saturday, October 21st. Nine equities research analysts have rated the stock with a hold rating and five have assigned a buy rating to the company. The company has an average rating of “Hold” and a consensus target price of $63.55.

In other Alkermes news, SVP Laurie Keating sold 6,249 shares of the stock in a transaction dated Wednesday, December 20th. The stock was sold at an average price of $121.20, for a total value of $757,378.80. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, Director Paul J. Mitchell sold 1,000 shares of the stock in a transaction dated Friday, December 1st. The shares were sold at an average price of $51.98, for a total value of $51,980.00. Following the completion of the transaction, the director now owns 9,000 shares of the company’s stock, valued at $467,820. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 136,417 shares of company stock valued at $7,259,391. 5.34% of the stock is owned by corporate insiders.

TRADEMARK VIOLATION WARNING: “Alkermes (ALKS) Given Daily News Impact Rating of 0.12” was posted by Watch List News and is the property of of Watch List News. If you are reading this report on another website, it was copied illegally and republished in violation of U.S. & international copyright & trademark law. The original version of this report can be read at

Alkermes Company Profile

Alkermes plc is a biopharmaceutical company. The Company is engaged in the researching, developing and commercializing pharmaceutical products that are designed to address medical needs of patients in therapeutic areas. The Company has a portfolio of marketed drug products and a clinical pipeline of products that address central nervous system (CNS) disorders, such as schizophrenia, depression, addiction and multiple sclerosis (MS).

Insider Buying and Selling by Quarter for Alkermes (NASDAQ:ALKS)

Receive News & Ratings for Alkermes Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alkermes and related companies with's FREE daily email newsletter.